Genenta Science S.p.A. (GNTA)
| Market Cap | 71.90M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.94M |
| Shares Out | 18.22M |
| EPS (ttm) | -0.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,250 |
| Open | 3.630 |
| Previous Close | 3.670 |
| Day's Range | 3.600 - 3.968 |
| 52-Week Range | 3.000 - 6.810 |
| Beta | 0.72 |
| Analysts | Strong Buy |
| Price Target | 15.00 (+280.06%) |
| Earnings Date | May 5, 2023 |
About GNTA
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition,... [Read more]
Analyst Forecast
According to one analyst, the rating for GNTA stock is "Strong Buy" and the 12-month stock price forecast is $15.0.
News
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial
Genenta to Present at Upcoming Scientific and Investor Conferences
MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of he...
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Canc...
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma
MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoi...
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing
MILAN, Italy and NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of he...
Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications
MILAN, Italy and NEW YORK, April 03, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopo...
FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme
MILAN and NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic s...
Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement
MILAN, N.Y., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene thera...
Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients
• Signs of intra-tumor pro-inflammatory state in patients• Temferon™ induced immune system reset in preclinical studies• Macrophage and T cell profiles in patients' tumor microenvironment echo preclin...
Genenta Provides First Half 2022 Business Update and Financial Results
MILAN, Italy and NEW YORK, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), (“Genenta” or the “Company”), a clinical stage immuno-oncology company developing a cell-based platform har...
Genenta to Present at Upcoming Investor Conferences
MILAN, Italy and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopo...
AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative
Think tank of Italian companies and entrepreneurs listed or to be listed on US capital markets Think tank of Italian companies and entrepreneurs listed or to be listed on US capital markets
Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA
MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immu...
Genenta Appoints Industry Veteran Tim Obara as Head of Business Development
Extensive experience in business development with AstraZeneca and GSK Extensive experience in business development with AstraZeneca and GSK
Genenta Files Annual Report on Form 20-F for Fiscal Year 2021
MILAN, Italy and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor ce...
Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme
No dose limiting toxicity observed in previous three dose level cohortsRepresents a 50% higher dose than highest prior levelUpdate of guidance for trial
Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma
Initial evidence of potential to modulate tumor microenvironment Initial evidence of potential to modulate tumor microenvironment
Genenta Announces Nomination of Mark A. Sirgo as Chair
35 years industry experience including as CEO and founder of public company
Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors
*** David Reardon, Luigi Naldini, Brad Loncar *** *** David Reardon, Luigi Naldini, Brad Loncar ***
Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme
Data to be presented at the 2022 annual meeting of American Association for Cancer Research Data to be presented at the 2022 annual meeting of American Association for Cancer Research
Genenta to Participate at Upcoming Investor Conferences
MILAN, Italy and NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell imm...
Genenta Closes Its Upsized Initial Public Offering of American Depository Shares
MILAN, Italy and NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor c...
Genenta Announces Pricing of Upsized Initial Public Offering
MILAN, Italy and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A., a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene...